Evidence map›Paper›PMID 41712874›Full record

ArticleJCO precision oncology2026

Sustained Response to Lorlatinib and Pemetrexed in

Matheus Sewastjanow-Silva, Maria E Cabanillas, Eduardo Andreazza Dal Lago, Mateus Trinconi Cunha, Mark Zafereo, Adel K El-Naggar, Renata Ferrarotto, Yasir Y Elamin, Luana Guimaraes de Sousa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matheus Sewastjanow-SilvaDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0003-4804-1891
Maria E CabanillasDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5124-1811
Eduardo Andreazza Dal LagoDivision of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0009-0003-6987-7740
Mateus Trinconi CunhaDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-9101-8553
Mark ZafereoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0001-7918-9739
Adel K El-NaggarDepartment of Anatomical Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-7175-9466
Renata FerrarottoDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-3561-215X
Yasir Y ElaminDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-5312-909X
Luana Guimaraes de SousaDepartment of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.ORCID 0000-0002-3516-7105

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41712874
PMCPMC12931856

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.